Irritable Bowel Syndrome With Constipation (IBS-C) Clinical Trial
Official title:
A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Safety and Efficacy of Tenapanor for the Treatment of Irritable Bowel Syndrome With Constipation (IBS-C) in Pediatric Patients 12 to Less Than 18 Years Old
This is a randomized, double-blind, placebo-controlled study to assess the efficacy, safety and tolerability of tenapanor (25 mg and 50 mg) in pediatric patients (≥12 and <18 years old) with IBS-C when administered twice daily (BID) for 12 consecutive weeks.
This study consists of 2-week screening period followed by 12 week randomized treatment period (RTP). At the beginning of the 2-week Screening period, patients who provide written assent will be fully assessed for eligibility into the study and will be asked to self-report daily information about the status of their IBS symptoms via an electronic diary (eDiary) device. Patient compliance with the eDiary will be monitored actively by the site staff and will be reviewed to determine eligibility at the end of screening. Eligible patients will be randomized to receive one of the study medications: tenapanor 25 mg BID, tenapanor 50 mg BID, or placebo. During the 12-week double-blind RTP, patients will continue recording daily assessments via the eDiary system as instructed and compliance with eDiary entries will be monitored on an ongoing basis. Patients will return for study visit every two or four weeks (Visits 3-6) and will undergo safety assessments at these visits. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02316899 -
Phase III Study to Evaluate the Efficacy and Safety of ASP0456 in Patients With Constipation Predominant Irritable Bowel Syndrome
|
Phase 3 | |
Completed |
NCT02493036 -
A Single-Dose, Open-Label, Study to Evaluate the Sustainability of the Effects of SYN-010 in Patients With IBS-C
|
Phase 2 | |
Completed |
NCT03471728 -
Post-marketing Surveillance of Linaclotide Tablet in Patients With Irritable Bowel Syndrome With Constipation or Chronic Constipation (Excluding Constipation Due to Organic Diseases)
|
||
Recruiting |
NCT05240521 -
Efficacy and Safety, Tolerability of GA-AT0119 in IBS-C
|
N/A | |
Completed |
NCT02495623 -
A Study of the Effect of SYN-010 on Subjects With IBS-C
|
Phase 2 | |
Completed |
NCT01880424 -
A Phase 3, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Trial of Linaclotide Administered Orally for 12 Weeks to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
|
Phase 3 | |
Completed |
NCT02078323 -
Investigation of Linaclotide's Effect on the Bi-directional Brain and Gut Axis in IBS-C Patients
|
N/A | |
Enrolling by invitation |
NCT05905926 -
Safety Study of Tenapanor for the Treatment of Pediatric Patients (6 to Less Than 18 Years Old) With IBS-C
|
Phase 3 |